Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Net Margin came in at 461.48% in Q1 2026, down 46150.0% YoY from N/an in Q1 2025, and down 101.33% on a QoQ basis from 34723.87% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Net Margin data on file, last reported at 461.48% in Q1 2026.
- Quarterly Net Margin fell 46150.0% year-over-year to 461.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95.44% (down 8482.0% YoY) and the FY2025 annual result came in at 30.16%, up 4988.0% from the prior year.
- Net Margin eased to 461.48% in Q1 2026, from 34723.87% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 34723.87% in Q4 2025 to a low of 461.48% in Q1 2026.
- A 5-year average of 1972.38% and a median of 41.67% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2025 — Net Margin soared 3474424 bps — and 2026, when it slumped 46150 bps.
- Tracing BCRX's Net Margin over 5 years: stood at 89.94% in 2022, then increased by 27 bps to 66.09% in 2023, then jumped by 69 bps to 20.37% in 2024, then soared by 170556 bps to 34723.87% in 2025, then plunged by 101 bps to 461.48% in 2026.
- The last three Net Margin figures came in at 461.48% (Q1 2026), 34723.87% (Q4 2025), and 8.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 35.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.92% |
| Mar 31, 2026 | -461.48% |
| Dec 31, 2025 | 34,723.87% |
| Sep 30, 2025 | 8.09% |
| Jun 30, 2025 | 3.11% |
| Mar 31, 2025 | 0.02% |
| Dec 31, 2024 | -20.37% |
| Sep 30, 2024 | -11.99% |
| Jun 30, 2024 | -11.59% |
| Mar 31, 2024 | -38.14% |
| Dec 31, 2023 | -66.09% |
| Sep 30, 2023 | -41.67% |
| Jun 30, 2023 | -91.31% |
| Mar 31, 2023 | -77.54% |
| Dec 31, 2022 | -89.94% |
| Sep 30, 2022 | -56.08% |
| Jun 30, 2022 | -89.82% |
| Mar 31, 2022 | -148.62% |
| Dec 31, 2021 | -37.70% |
| Sep 30, 2021 | -143.44% |